- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04008771
Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases
July 3, 2019 updated by: 2C Tech Corp
A Phase 1 Safety And Effectiveness Study of Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases
This study was a prospective, open label feasibility study conducted at a single clinical site (APEC, Mexico City) to evaluate the safety and preliminary effectiveness of the SeeQ device, with each patient's serving as his/her own contralateral control.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico City, Mexico
- Asociacion Para Evitar La Ceguera En Mexico, I.A.P. (APEC)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects, 21 years of age or older.
- Subjects with a history of degenerative retinal diseases such as RP.
- Subjects with a documented history of disease progression.
- Willing and able to return for all study visits.
- Willing and able to provide written informed consent for the Clinical Study.
- Subjects with a BCVA greater or equal to 20/16000 must have consistent fixation demonstrated by indirect ophthalmoscopy with a small circle of light and by consistent location of remaining central visual field detected by VFA.
- Study Arm A: The best corrected visual acuity must be between 20/16000 and HM as tested by ETDRS chart and ERG B wave amplitude.
- Study Arm B: The best-corrected visual acuity must be between 20/60 and 20/16000 and visual field of central 15 degrees (III static 30-2 protocol, 31.5 ASB background) greater than 10 dB loss, as determined by a Humphrey Instruments, Inc. Visual Field Analyzer (VFA).
Exclusion Criteria:
- Subjects with significant lens or corneal pathology (either history of or current) in the study eye other than retinal diseases.
- Subjects with high myopia in the study eye (axial length greater than or equal to 26.0 millimeters by ultrasound or spherical equivalent at the spectacle plane greater than -8.0 diopters.)
- Subjects whose retinal disease status has been stable for more than 90 days.
- Subjects with history of iritis or uveitis in either eye.
- Subjects who have monocular vision.
- Subjects with a history of retinal detachment or tear in either eye.
- Subjets with unstable IOP (i.e. > 30 mmHg in the past six months) or IOP of > 24 mm Hg at enrollment while under medical control. Subjects may be on topical medications to control their IOP.
- Subjects with an aphakic study ete or if pseudophakic, cataract extraction surgery more than 6 months prior to study enrollment.
- Subjects with a history of ocular trauma of any type in the study eye.
- Subjects with media opacities or abnormalities that would preclude observation of the retina in the study eye, per the investigator's judgement.
- Subjects that have undergone any previous vitrectomy (either anterior or pars plana vitrectomy in the study eye).
- Subjects with a history of cataract surgery complication in the study eye.
- Subjects that have undergone previous photocoagulation of the retina in the study eye.
- Subjects anticipated requiring cataract extraction in the study eye within the next six (6) months.
- Subjects with congenital eye malformations.
- Recurrent uveitis or history of uveitis in either eye.
- Macular edema or history of macular edema in the study eye where central macular thickness is greater than 275 microns by OCT at baseline.
- Ongoing ocular infection or inflammation in the study eye.
- Pregnant or nursing females.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Severe Disease
Subjects with baseline BCVA between 20/16000 and hand motion (HM).
Subjects received 2.0 μM concentration intravitreal injections on each Day 0 and Day 21.
|
SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
|
Experimental: Moderate to Severe Disease
Subjects with baseline BCVA from 20/60 to 20/16000.
The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten [10]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
|
SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Best Corrected Visual Acuity "BCVA"
Time Frame: Measured at Baseline through Day 42
|
Measured at Baseline through Day 42
|
|
Change in Contrast Sensitivity
Time Frame: Measured at Baseline through Day 42
|
Contrast sensitivity was measured utilizing a sin wave (Vistech) contrast sensitivity chart under photopic conditions
|
Measured at Baseline through Day 42
|
Change in ERG Amplitude
Time Frame: Measured at Baseline through Day 42
|
ERG amplitude was measured using Poland Consult ERG equipment
|
Measured at Baseline through Day 42
|
Change in Visual Fields
Time Frame: Measured at Baseline through Day 42
|
Visual Field improvement is assessed using a Humphrey/Zeiss Visual Field Analyzer
|
Measured at Baseline through Day 42
|
Change in Functional Vision
Time Frame: Measured at Baseline through Day 42
|
Functional Vision is tested using Object identification and White line orientation testing
|
Measured at Baseline through Day 42
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of Effect
Time Frame: Measured at Baseline through Day 42
|
Measured at Baseline through Day 42
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Ocular Adverse Events
Time Frame: Measured at Baseline through Day 42
|
Safety Endpoint
|
Measured at Baseline through Day 42
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2014
Primary Completion (Actual)
December 19, 2014
Study Completion (Actual)
December 19, 2014
Study Registration Dates
First Submitted
June 25, 2019
First Submitted That Met QC Criteria
July 3, 2019
First Posted (Actual)
July 5, 2019
Study Record Updates
Last Update Posted (Actual)
July 5, 2019
Last Update Submitted That Met QC Criteria
July 3, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SeeQ 101.A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinitis Pigmentosa
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasCompletedGene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaUnited Kingdom, United States
-
Oslo University HospitalRecruitingRetinitis Pigmentosa | Retinitis Pigmentosa 11Norway
-
Jinnah Burn and Reconstructive Surgery Centre,...The Layton Rahmatullah Benevolent Trust (LRBT) Free Eye Hospital, Township... and other collaboratorsRecruitingRetinitis Pigmentosa (RP)Pakistan
-
AbbVieActive, not recruitingAdvanced Retinitis PigmentosaUnited States
-
jCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)CompletedRetinitis Pigmentosa (RP)United States
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaBelgium, Canada, United States, Israel, United Kingdom, Spain, Denmark, France, Italy, Netherlands, Switzerland
-
Janssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
GenSight BiologicsRecruitingNon-syndromic Retinitis PigmentosaUnited States, France, United Kingdom
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, Canada, Israel, United Kingdom, Spain, Denmark, France, Belgium, Italy, Netherlands, Switzerland
-
BiogenCompletedX-Linked Retinitis PigmentosaUnited States, United Kingdom